TY - JOUR
T1 - Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185
AU - Bargmann, Cornelia I.
AU - Hung, Mien Chie
AU - Weinberg, Robert A.
N1 - Funding Information:
The authors wish to thank Mike Gilman and David Stern for critically reviewing this manuscript, Daria Maggio and Jayne Kassel for excellent technical support, and Wayne Brown for synthesizing oligonucleotides. C. I. B. was supported by a grant from the Education Foundation of America, M. -C. H. was supported by the Cancer Research Institute, and R. A. W. is an American Cancer Society Research Professor. This work was supported by grants from the American Business Cancer Research Foundation and the National Cancer Institute Grant cA39984-01.
PY - 1986/6/6
Y1 - 1986/6/6
N2 - The neu oncogene, which is frequently activated in neuro- and glloblastomas of BDIX rats, was originally identified in the NIH 3T3 focus-forming assay. cDNA clones of the normal and transforming alleles of neu have been isolated. When these clones are inserted into the expression vector pSV2, they direct the synthesis of p185, the neu gene product. The transforming cDNA clone yields foci when transfected onto a NIH 3T3 monolayer, but the normal cDNA does not. The construction of in vitro recombinants between the normal and transforming cDNAs has allowed the determination of the mutation responsible for the activation of the neu proto-oncogene. A single point mutation changes a valine in the transmembrane domain of the predicted protein product insert to a glutamic acid. The DNAs from four independent cell lines containing activated neu oncogenes contain the identical mutation at this position.
AB - The neu oncogene, which is frequently activated in neuro- and glloblastomas of BDIX rats, was originally identified in the NIH 3T3 focus-forming assay. cDNA clones of the normal and transforming alleles of neu have been isolated. When these clones are inserted into the expression vector pSV2, they direct the synthesis of p185, the neu gene product. The transforming cDNA clone yields foci when transfected onto a NIH 3T3 monolayer, but the normal cDNA does not. The construction of in vitro recombinants between the normal and transforming cDNAs has allowed the determination of the mutation responsible for the activation of the neu proto-oncogene. A single point mutation changes a valine in the transmembrane domain of the predicted protein product insert to a glutamic acid. The DNAs from four independent cell lines containing activated neu oncogenes contain the identical mutation at this position.
UR - http://www.scopus.com/inward/record.url?scp=0022485548&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022485548&partnerID=8YFLogxK
U2 - 10.1016/0092-8674(86)90779-8
DO - 10.1016/0092-8674(86)90779-8
M3 - Article
C2 - 2871941
AN - SCOPUS:0022485548
SN - 0092-8674
VL - 45
SP - 649
EP - 657
JO - Cell
JF - Cell
IS - 5
ER -